Menus Subscribe Search

Follow us


vaccine-diplomacy

(PHOTO: ALEXANDER RATHS/SHUTTERSTOCK)

Next Steps in U.S.-Iran Diplomacy: Vaccines

• November 06, 2013 • 11:00 AM

(PHOTO: ALEXANDER RATHS/SHUTTERSTOCK)

Two vaccine scientists—one American, one Iranian—offer a unique way to give the nascent relationship between their two countries a shot in the arm.

September’s historic dialogue between President Obama and Iran’s President Rouhani together with calls to seek constructive engagement opens the door to a little known but powerful foreign policy instrument, which could simultaneously create new life-saving vaccines.

The cornerstone of vaccine diplomacy is two or more countries putting aside their ideological differences to engage in an intense and focused scientific collaboration and produce an urgently needed technology that serves humanity.

In modern times, the first triumph of vaccine diplomacy occurred in the decade that began following the death of Stalin in 1953. Together, Dr. Albert B. Sabin in the U.S. and his Soviet virology counterpart each received back channel permission to jointly develop and then test a prototype oral polio vaccine on more than 10 million children in the USSR. The successful results led to the licensure of the oral polio vaccine in 1962, the elimination of polio in the U.S. in 1979, and ultimately the eradication of polio in all but three countries. Similar international cooperation with the Soviets to improve the vaccine was a key step resulting in the global eradication of smallpox.

Both the U.S. and Iran are under serious threat from several neglected tropical diseases that have emerged in our countries because of a variety of factors, including extreme poverty, urbanization, population growth, and possibly climate change.

Today, both the U.S. and Iran are under serious threat from several neglected tropical diseases that have emerged in our countries because of a variety of factors, including extreme poverty, urbanization, population growth, and possibly climate change. They include dengue fever, a mosquito-transmitted viral infection that results in hemorrhage, shock, and death. Dengue has recently emerged on the U.S. Gulf Coast and in southeastern Iran neighboring Pakistan. Kinetoplastid infections such as Chagas disease, a cause of severe heart disease, are now widespread among the poor in Texas and the southern U.S. where over 300,000 cases occur, while leishmaniasis, a severely disfiguring skin disease, affects 100,000 or more Iranians, and has also emerged in Texas and Oklahoma. Worm infections are still commonly found in impoverished areas in both countries, and where infections overall account for a significant amount of the health care burdens.

Both the U.S. and Iran would benefit enormously from research leading to the development and joint testing of vaccines against these neglected tropical diseases. Our recent investigations reveal that the extreme poor living in middle income and wealthy countries suffer as much from these conditions as those in the poorest countries in Africa, so that all of the world’s people living in poverty would benefit from new vaccines. Unfortunately because there is no major commercial market for neglected tropical disease vaccines (with the exception of dengue) the multinational pharmaceutical companies are not attempting to produce them.

In Iran, both fundamental and epidemiological research is conducted on a number of neglected tropical diseases including Crimean-Congo hemorrhagic fever, West Nile virus infection, brucellosis, leptospirosis, echinococcosis, fascioliasis, and intestinal worms. Iranian scientists have made several attempts at vaccines for some of their tropical infections, including prototype leishmaniasis vaccines made from live or killed whole parasites. However the efficacy and safety of such vaccines has thwarted further development along those lines. Nascent efforts to develop a safer and more effective vaccine through advanced genetic engineering—so called recombinant vaccines—are beginning, but a U.S. collaboration to accelerate their development will be needed. In addition, in order to enhance the efficacy of a recombinant leishmaniasis vaccine there may be requirements to add novel substances that increase the body’s immune response, but the best of these immunostimulants are currently only available in the West and can’t easily (or possibly legally) be shipped to Iran. Ultimately such steps would help to ensure future success in terms of producing a vaccine that would be widely used in the Middle East and adjoining regions of North Africa and Central Asia.

Indeed, such vaccines could be developed in the non-profit sector through joint activities of U.S.-based product development partnerships through support of the Gates Foundation, the National Institutes of Health, and other sources, together with Iranian institutions, such as the Tehran University and the Razi Serum and Vaccine Institute. However, meaningful scientific collaboration to actually produce such products is not currently practical given both financial and political constraints, including the need to overcome fears of potentially producing so-called “dual use” technologies. Therefore, high-level discussions need to first take place between the U.S. Department of State and its Iranian counterpart to actively encourage and support joint vaccine development, and then implement steps to effectively shape policy and launch the first stages of vaccine product development, including antigen discovery, process development, pilot manufacture, regulatory filing, and initial clinical testing.

Vaccine diplomacy’s modern day track record is impressive, having led to the global eradication of smallpox and the near-elimination of polio. It occurred because the U.S. and USSR put aside their differences during the Cold War. We now have an opening and potential path to do the same between the U.S. and Iran.

Peter Hotez and Mohammad Rokni
Peter Hotez is president of the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development; dean of the National School of Tropical Medicine, Baylor College of Medicine; and Baker Institute Fellow in Disease and Poverty. Mohammad B. Rokni is professor of Medical Parasitology and Mycology in the School of Public Health at the Tehran University of Medical Sciences.

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

October 20 • 2:00 PM

The Risk of Getting Killed by the Police If You Are White, and If You Are Black

An analysis of killings by police shows outsize risk for young black males.


October 20 • 12:00 PM

Love and Hate in Israel and Palestine

Psychologists find that parties to a conflict think they’re motivated by love while their enemies are motivated by hate.


October 20 • 11:00 AM

My Dog Comes First: The Importance of Pets to Homeless Youth

Dogs and cats have both advantages and disadvantages for street-involved youth.


October 20 • 10:00 AM

Homophobia Is Not a Thing of the Past

Despite growing support for LGBT rights and recent decisions from the Supreme Court regarding the legality of same-sex marriage, the battle for acceptance has not yet been decided.


October 20 • 8:00 AM

Big Boobs Matter Most

Medical mnemonics are often scandalous and sexist, but they help the student to both remember important facts and cope with challenging new experiences.


October 20 • 6:00 AM

When Disease Becomes Political: The Likely Electoral Fallout From Ebola

Will voters blame President Obama—and punish Democrats in the upcoming mid-term elections—for a climate of fear?


October 20 • 4:00 AM

Coming Soon: The Anatomy of Ignorance


October 17 • 4:00 PM

What All Military Families Need to Know About High-Cost Lenders

Lessons from over a year on the beat.


October 17 • 2:00 PM

The Majority of Languages Do Not Have Gendered Pronouns

A world without “he.” Or “she.”


October 17 • 11:01 AM

How to Water a Farm in Sandy Ground

Physicists investigate how to grow food more efficiently in fine-grained soil.


October 17 • 10:00 AM

Can Science Fiction Spur Science Innovation?

Without proper funding, the answer might not even matter.


October 17 • 8:00 AM

Seattle, the Incredible Shrinking City

Seattle is leading the way in the micro-housing movement as an affordable alternative to high-cost city living.


October 17 • 6:00 AM

‘Voodoo Death’ and How the Mind Harms the Body

Can an intense belief that you’re about to die actually kill you? Researchers are learning more about “voodoo death” and how it isn’t limited to superstitious, foreign cultures.


October 17 • 4:00 AM

That Arts Degree Is Paying Off

A survey of people who have earned degrees in the arts find they are doing relatively well, although their education didn’t provide much guidance on managing a career.


October 16 • 4:00 PM

How (Some) Economists Are Like Doomsday Cult Members

Cognitive dissonance and clinging to paradigms even in the face of accumulated anomalous facts.


October 16 • 2:00 PM

The Latest—and Most Mysterious—Player in the Nasty Battle Over Net Neutrality

As the FCC considers how to regulate Internet providers, the telecom industry’s stealth campaign for hearts and minds encompasses everything from art installations to LOLcats.


October 16 • 12:00 PM

How Many Ads Is Too Many Ads?

The conundrum of online video advertising.


October 16 • 11:00 AM

Unlocking Consciousness

A study of vegetative patients closes in on the nature of consciousness.


October 16 • 10:00 AM

The False Promises of Higher Education

Danielle Henderson spent six years and $60,000 on college and beyond. The effects of that education? Not as advertised.


October 16 • 8:00 AM

Faster Justice, Closer to Home: The Power of Community Courts

Community courts across the country are fighting judicial backlog and lowering re-arrest rates.


October 16 • 6:00 AM

Killing Your Husband to Save Yourself

Without proper legal instruments, women with abusive partners are often forced to make a difficult choice: kill or be killed.


October 16 • 4:00 AM

Personality Traits Linked to Specific Diseases

New research finds neurotic people are more likely to suffer a serious health problem.


October 16 • 2:00 AM

Comparing Apples to the Big Apple: Yes, Washington, D.C., Is More Expensive Than New York City

Why shouldn’t distant locales tied to jobs in the urban core count in a housing expenditure study?


October 15 • 4:00 PM

Why Asian American Parents Are the Least Likely to Spank Their Kids

Highly educated, middle-class parents are less likely to use corporal punishment to discipline their children than less-educated, working-class, and poor parents.


October 15 • 2:00 PM

The Federal Government’s New Doctor Payments Website Is Worthy of a Recall

Charles Ornstein takes a test drive using the federal government’s new website for drug and device payments and finds it virtually unusable.


Follow us


Love and Hate in Israel and Palestine

Psychologists find that parties to a conflict think they're motivated by love while their enemies are motivated by hate.

How to Water a Farm in Sandy Ground

Physicists investigate how to grow food more efficiently in fine-grained soil.

Unlocking Consciousness

A study of vegetative patients closes in on the nature of consciousness.

Advice for Emergency Alert Systems: Don’t Cry Wolf

A survey finds college students don't always take alerts seriously.

Brain’s Reward Center Does More Than Manage Rewards

Nucleus accumbens tracks many different connections in the world, a new rat study suggests.

The Big One

One company, Amazon, controls 67 percent of the e-book market in the United States—down from 90 percent five years ago. September/October 2014 new-big-one-5

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.